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The N-aryl carbamate URB602 (biphenyl-3-
ylcarbamic acid cyclohexyl ester) is an inhibitor
of monoacylglycerol lipase (MGL), a serine
hydrolase involved in thebiological deactivation
of the endocannabinoid 2-arachidonoyl-sn-
glycerol (2-AG). Here, we investigated the
mechanism by which URB602 inhibits purified
recombinant rat MGL by using a combination
of biochemical and structure-activity relation-
ship (SAR) approaches. We found that URB602
weakly inhibits recombinant MGL (IC50 = 223 ±
63 mM) through a rapid and noncompetitive
mechanism. Dialysis experiments and SAR
analyses suggest that URB602 acts through
a partially reversible mechanism rather than by
irreversible carbamoylation of MGL. Finally,
URB602 (100 mM) elevates 2-AG levels in hippo-
campal slice cultures without affecting levels
of other endocannabinoid-related substances.
Thus, URB602 may provide a useful tool by
which to investigate the physiological roles of
2-AG and explore the potential interest of MGL
as a therapeutic target.
INTRODUCTION
2-Arachidonoyl-sn-glycerol (2-AG) is a major monoacyl-
glycerol (MAG) species present in mammalian tissues
and, along with anandamide, is an endogenous ligand
for cannabinoid (CB) receptors [1, 2]. These lipid messen-
gers, called endocannabinoids, are produced on demand
through cleavage of membrane phospholipid precursors
and are implicated in a variety of short-range signaling
processes [2, 3]. In the central nervous system (CNS),
the endocannabinoids activate CB1 receptors on presyn-
aptic terminals to regulate calcium- and potassium-chan-Chemistry & Biology 14, 1357–136nel activity, as well as neurotransmitter release [4]. These
neuromodulatory effects have a wide range of functional
consequences. In particular, their proposed involvement
in the regulation of pain, appetite, and mood has signifi-
cant therapeutic potential and highlights the importance
of understanding the mechanisms by which endocannabi-
noids are produced and eliminated [5].
The biological deactivation of 2-AG and anandamide is
thought to require a two-step process involving carrier-
mediated transport into cells and subsequent intracellular
hydrolysis [6–8]. 2-AG is hydrolyzed by two or more mono-
acylglycerol lipase (MGL) enzymes [9, 10], one of which
has been molecularly cloned [11, 12], whereas ananda-
mide is hydrolyzed by fatty-acid amide hydrolase (FAAH)
[13] and N-acylethanolamine acid amidase (NAAA) [14].
The cloned MGL is a 303 amino acid serine hydrolase
that resides in the cell cytosol and cleaves MAGs into fatty
acid and glycerol [11, 12]. Three lines of evidence suggest
that this enzyme plays a key role in the physiological deac-
tivation of 2-AG in the CNS. First, MGL is expressed at high
levels in the rodent brain [12], where it is predominantly
found in presynaptic nerve terminals of both excitatory
and inhibitory neurons [15]. Second, virally induced
overexpression of MGL dampens N-methyl-D-aspartate
(NMDA)-dependent accumulation of 2-AG in rat cortical
neurons [12], whereas RNAi-mediated silencing of consti-
tutive MGL expression increases 2-AG levels in HeLa cells
[16]. Finally, pharmacological blockade of intracellular
MGL activity by two structurally unrelated inhibitors,
URB602 (biphenyl-3-ylcarbamic acid cyclohexyl ester)
and methylarachidonylfluorophosphonate (MAFP), ele-
vates 2-AG levels and enhances 2-AG-mediated signaling
in neurons [17, 18]. For example, microinjections of
URB602 or MAFP in the periaqueductal gray matter of
the midbrain selectively increase 2-AG levels, but not
anandamide levels, and enhance CB1 receptor-mediated
stress-induced analgesia in rats [17]. Furthermore, admin-
istration of URB602 or MAFP prolongs endocannabinoid-
mediated changes in synaptic strength in acutely
dissected rat hippocampal slices [18]. Even further, admin-
istration of URB602 in rodents has been shown to produce5, December 2007 ª2007 Elsevier Ltd All rights reserved 1357
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Characterization of the MGL Inhibitor URB602Figure 1. Expression of Recombinant
MGL
(A) Coomassie staining (left) and western blot
(right) analyses of purified recombinant MGL
expressed in E. coli.
(B) Time course of oleic acid (OA) production
from 2-oleoyl-sn-glycerol (2-OG) in the pres-
ence of purified MGL (10 ng). Results are the
average of two experiments, each performed
in duplicate.anti-inflammatory and antinociceptive effects that are
selectively blocked by CB2 receptor antagonists [19, 20].
Thus, URB602 and MAFP may be used to investigate the
physiological roles of 2-AG and the pharmacological
potential of MGL inhibition, provided that appropriate
precautions are taken to control for the limitations of these
agents. In particular, questions that remain to be ad-
dressed concern (i) the molecular identity of the MAG-
hydrolyzing enzyme(s) targeted by URB602 and MAFP;
and (ii) the mechanisms by which URB602 and MAFP in-
hibit this enzyme(s). Answering these questions may help
resolve current inconsistencies in the literature, such as
a recent study reporting that URB602 exerts little or no
inhibitory effect on 2-AG hydrolysis in broken-cell prepara-
tions of brain tissue [21]. Therefore, in the present study,
we have sought to (i) reexamine the inhibitory effects of
URB602 on MGL activity, by using both a purified recombi-
nant MGL and intact brain neurons; and (ii) investigate the
mechanism by which URB602 inhibits cloned MGL, by
using an approach that combines kinetic, dialysis, and
structure-activity relationship (SAR) analyses.
RESULTS AND DISCUSSION
Expression of Recombinant MGL
We overexpressed recombinant rat MGL in E. coli and
purified it by affinity chromatography. Sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
analyses of the purified protein, followed by Coomassie
blue staining or immunoblotting, revealed a single band
that closely matched the calculated molecular weight of
histidine-tagged cloned rat brain MGL (35.7 kD) (Fig-
ure 1A). As expected, recombinant MGL hydrolyzed the
MAG substrate 2-oleoylglycerol (2-OG) in a time-depen-
dent and protein concentration-dependent manner
(Figure 1B; data not shown).
Inhibition of Recombinant MGL
Figure 2A shows the concentration-dependent inhibition
of purified recombinant MGL by URB602 (IC50 = 223 ±
63 mM, n = 4) and by the broad-spectrum lipase inhibitor
MAFP (35 ± 13 nM, n = 3) under standard conditions
(10 min, 37C) [22–24]. In some experiments, we mea-
sured the ability of URB602 to inhibit MGL activity in assays1358 Chemistry & Biology 14, 1357–1365, December 2007 ª20of 2.5 min duration, and we obtained similar results across
experiments (IC50 = 185 ± 13 mM, n = 3). Figure 2A also
illustrates the effect of the MGL inhibitor N-arachidonyl-
maleimide (NAM) [25] (IC50 = 46 ± 7 nM, n = 3). Figure 2B
depicts the effects of URB602, MAFP, and NAM on re-
combinant MGL overexpressed in HeLa cells (IC50 values:
URB602, 81 ± 13 mM; MAFP, 23 ± 0.1 nM; NAM, 41 ± 19 nM;
n = 3–4). Notably, URB602 was significantly more potent
at inhibiting nonpurified MGL expressed in HeLa cells
than purified MGL expressed in E. coli (p < 0.05, unpaired
Student’s t test), suggesting that posttranslational modifi-
cations or differences in the enzyme assay environment
may alter the inhibitory potency of this compound. An al-
ternate interpretation is that HeLa cells express another
2-OG-hydrolyzing enzyme that has higher sensitivity to
URB602 than the cloned MGL.
Inhibition of Cerebellar MGL
The ability of URB602, MAFP, and NAM to inhibit MGL
activity was further investigated by using cerebellar mem-
branes. A previous study with this preparation reported no
effect of URB602 on 2-AG hydrolysis [21]. We found, how-
ever, that both URB602 and NAM inhibited MAG hydroly-
sis in cerebellar membranes in a concentration-depen-
dent manner (Figure 2C). Interestingly, neither agent
achieved complete inhibition, even when tested at con-
centrations that were maximally effective on cloned
MGL. By contrast, MAFP virtually eliminated 2-OG hydro-
lysis, suggesting that cerebellar membranes contain
multiple MGL activities, and that URB602 and NAM only
affect a subset of such activities.
Kinetic Analyses of MGL Inhibition
To explore the mechanism by which URB602 inhibits MGL,
we measured recombinant MGL activity at various
substrate concentrations, in the absence or presence of
URB602 (0.3 and 1 mM) (Figure 3A). Incubation with
URB602 resulted in an increase in the Michaelis-Menten
constant (KM) and a decrease in the maximal velocity
(Vmax) of the MGL reaction (Table 1). This result suggests
that URB602 inhibits MGL activity in a noncompetitive man-
ner. In particular, the reciprocal effect of URB602 on KM and
Vmax indicates that the inhibitor may bind withgreater affinity
to the freeenzymethan the enzyme-substratecomplex [26].07 Elsevier Ltd All rights reserved
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We next examined the time dependence of MGL inhibition
by URB602 (0.3 mM). Maximal percent inhibition occurred
within 2 min of URB602 addition, and this level remained
unchanged for up to 1 hr (Figures 3B and 3C). To deter-
mine whether URB602 itself may be hydrolyzed by MGL
during the incubation period, we measured URB602 con-
centrations by using liquid chromatography/mass spec-
trometry (LC/MS). Although a small decrease in URB602
levels was seen immediately after initiating the incubation,
possibly due to absorption to glassware, no further change
occurred for the rest of the experiment (Figure 3C). The
Figure 2. Inhibition of MGL Activity by Various Agents
(A and B) Effects of URB602 (circles, n = 4), MAFP (triangles, n = 3), or
NAM (squares, n = 3) on either (A) purified MGL expressed in E. coli or
(B) MGL expressed in HeLa cells. Results are expressed as mean ±
SEM; each assay isperformed in duplicate.
(C) Inhibition of MGL activity in cerebellar membranes by URB602,
MAFP, or NAM. Results are expressed as mean ± SEM (n = 3); each
assay is performed in triplicate. *p < 0.05, **p < 0.01, ANOVA, followed
by Dunnett’s test; #p < 0.05, unpaired Student’s t test.Chemistry & Biology 14, 1357–136results indicate that URB602 (i) inhibits MGL in a time-inde-
pendent manner, and (ii) does not serve as a substrate
for MGL.
Reversibility of MGL Inhibition
The O-aryl carbamate URB597 (cyclohexylcarbamic acid
30-carbamoylbiphenyl-3-yl ester) inhibits FAAH activity
by an irreversible mechanism that likely involves carba-
moylation of an active-site serine residue of the enzyme
[27, 28]. To test whether URB602, an N-aryl carbamate,
also inhibits MGL irreversibly, we incubated the purified
enzyme in the presence of URB602 (30 and 100 mM) and
then subjected the incubation mixture to extensive dialy-
sis (24 hr, 0C–4C). Dialysis partially reversed the inhibi-
tion of MGL activity by URB602 (Figure 3D), suggesting
that this agent inhibits MGL through a mechanism that is
at least partially reversible.
Structure-Activity Relationship Studies
We also investigated the chemical requirements for MGL
inhibition by URB602 (Table 2). A series of modifications
were made to the two substituents on the carbamate
moiety, focusing on the importance of the substituent aro-
maticity (3a), the ester moiety (3j and 3l), N-alkylation (3o),
the shape of the N-biphenyl-3-yl group (3b, 3d–3g, and
3k), the role of theO-cyclohexyl group (3c), and the poten-
tial of the O-substituent to serve as a leaving group by
mimicking the glycerol fragment of 2-AG (3h, 3i, 3m, and
3n). Finally, as our kinetic and dialysis results challenged
the role of the carbamate group in MGL inhibition,
we replaced this group with various isosteric moieties
(4a, 5, and 6). Only one compound in this focused series,
the noncarbamate derivative 4a, was found to be more
effective than URB602 at inhibiting MGL activity (IC50 =
115 mM) (Table 2). Because compound 4a retains a high
steric similarity with URB602, but has a much lower ten-
dency to give a covalent bond with a nucleophilic serine,
this result supports the possibility that URB602 and 4a
are not active site-directed MGL inhibitors.
Recently, a carbamate, SPB 01403 (n-butylcarbamic
acid 4-[4,5-dihydrothiazol-2-yl]phenyl ester), that inhibits
MAG-hydrolyzing activity in rat cerebellar membranes
with an IC50 value of 31 mM has been reported [29] (Fig-
ure 4). Although it belongs to the same chemical class
as URB602, this compound has a carbamate group with
a different electronic environment, due to the presence
of an aromatic O-substituent with an electron-withdrawing
group in a conjugated position. Although the mechanism
of this inhibitor has not been elucidated, it may differ
from that which is reported here for URB602, given the
large difference in reactivity between their carbamate
fragments.
Effect of URB602 on 2-AG and Anandamide
Levels in Neurons
Previous studies indicate that URB602 protects endoge-
nous 2-AG from degradation in intact brain tissue [17, 18].
Thus, as an additional test of the ability of URB602 to
selectively inhibit MGL, we examined the effects of this5, December 2007 ª2007 Elsevier Ltd All rights reserved 1359
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Characterization of the MGL Inhibitor URB602Figure 3. Characterization of theMecha-
nism of MGL Inhibition by URB602
(A) Michaelis-Menten analysis of the MGL re-
action in the presence of vehicle (DMSO, 1%)
(circles, n = 4), 0.3 mM URB602 (triangles,
n = 3), or 1 mM URB602 (squares, n = 3). Re-
sults are expressed as mean ± SEM.
(B) Time course of the MGL reaction in the
presence of 1% DMSO (circles) or 0.3 mM
URB602 (triangles). Results are expressed as
mean ± SEM (n = 5).
(C) Changes in MGL inhibition over time, re-
plotted as the percent of maximal inhibition
(closed squares), are shown. Changes in
URB602 concentration over time, plotted as
thepercent of initial concentration (open trian-
gles), are also shown. Results are expressed
as mean ± SEM (n = 3).
(D) Effects of URB602 on MGL activity before
(open bars) and after (closed bars) dialysis
(24 hr, 0C–4C). Results are expressed as
mean ± SEM (n = 6). **p < 0.01, ***p < 0.001,
unpaired Student’s t test.agent on 2-AG content in rat hippocampal slices in
primary cultures. As shown in Figure 5A, treatment with
URB602 (100 mM, 25 min) produced a significant elevation
in 2-AG levels compared to vehicle (0.1% DMSO in Dul-
becco’s modified Eagle’s medium) (n = 5). In the same
slices, the levels of the FAAH substrates anandamide
(Figure 5B) and palmitoylethanolamide (PEA) (Figure 5C)
were not affected. These findings suggest that URB602
inhibits the degradation of 2-AG without affecting that of
other endocannabinoid-related substances.
SIGNIFICANCE
In the present study, we show that the N-aryl carba-
mate URB602 inhibits purified recombinant rat brain
MGLand increases 2-AG levels in intact brain neurons.
We further show that MGL inhibition by URB602
occurs through a rapid, noncompetitive, and partially
reversible mechanism, suggesting that URB602—
unlike O-aryl carbamate FAAH inhibitors such as
URB597 [27]—does not covalently modify MGL. SAR
studies confirm this possibility, pointing to substituted
ureas as a starting point for the discovery of novel
MGL inhibitors. Such agents are important for three
Table 1. Michaelis-Menten Constant and Maximal
Rate of Reaction for Purified Recombinant MGL
Expressed in E. coli
URB602
(mM) 0 0.3 1
KM (mM) 16.92 ± 3.188 27.05 ± 2.045 32.11 ± 1.083
Vmax
(pmol/
min/ng)
120.6 ± 12.44 106.1 ± 2.750 82.68 ± 6.273
Michaelis-Menten constant, KM; maximal rate of reaction,
Vmax. Data are represented as mean ± SEM (average of three
experiments performed in triplicate).1360 Chemistry & Biology 14, 1357–1365, December 2007 ª2reasons. First, they may help uncover specific func-
tions served by 2-AG in endocannabinoid signaling.
Second, they may provide an experimental tool by
which to validate MGL as a therapeutic target. Last,
they may serve as chemical scaffolds for the develop-
ment of drug-like MGL inhibitors with potential appli-
cations in the treatment of stress-related disorders
[17], pain [19], and inflammation [20]. Thus, despite
its limited potency, URB602 remains a useful tool by
which to investigate the roles of 2-AG and validate
MGL as a pharmacological target.
EXPERIMENTAL PROCEDURES
Chemicals
MAFP and NAM were purchased from Cayman Chemical (Ann Arbor,
MI), 2-OG was purchased from Sigma-Aldrich (St. Louis, MO), and
2-[2H8]-AG was purchased from Cayman Chemical; [
2H4]-anandamide
and [2H4]-palmitoylethanolamide were synthesized in the lab [30].
Chemistry
All chemicals were purchased from Sigma-Aldrich in the highest qual-
ity commercially available. Solvents were RP grade, unless otherwise
indicated. Chromatographic separations were performed on open silica-
gel columns by flash chromatography (Kieselgel 60, 0.040–0.063 mm,
Merck). The weight ratio between the material loaded in the column
and the stationary phase was about 1:50. Thin-layer chromatography
(TLC) analyses were performed on precoated silica-gel sheets (Kie-
selgel 60 F254, Merck). Melting points were determined on a Bu¨chi
SMP-510 capillary melting-point apparatus. EI-MS spectra (70 eV)
were recorded with a Fisons Trio 1000 spectrometer; only molecular
ions (M+) and base peaks are given. 1H-NMR spectra were recorded
on an AVANCE Bruker 200 spectrometer; chemical shifts are
reported in d scale and were measured by using the central peak
of the solvent. Infrared spectra (IR) were obtained on a Shimadzu
FT-8300, or a Nicolet Avatar, spectrometer; absorbances are re-
ported in n (cm1).
Synthetic Procedures
URB602 was synthesized as previously reported [17]. Carbamates
3a–3l were prepared by addition of an appropriate amine (1) and an
alcohol (2) to carbonyldiimidazole (CDI); all reagents are commercially007 Elsevier Ltd All rights reserved
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Characterization of the MGL Inhibitor URB602Table 2. IC50 Values for Inhibition of Purified
Recombinant MGL by Various URB602 Derivatives
Compound Structure IC50 (mM)
URB602 223 ± 63
3a >300
3b >300
3c >300
3d >300
3e >300
3f >300
3g >300
3h >300
3i >300
3j >300
3k >300
3l 243 (n = 2)
3 m >300
3n >300
3o >300Chemistry & Biology 14, 1357–13available, except 5-hydroxy-2,2-dimethyl-1,3-dioxane (2a), which was
prepared according to literature [31], biphenyl-3-ylamine (1a) [32],
5-phenyl-1-pentylamine (1c) [33], and substituted anilines 1d–1f. 1d
and 1e were obtained by a Suzuki coupling of 3-bromoaniline and
the appropriate boronic acid. 1f resulted from coupling of potassium
3-phenylphenolate and 3-bromoaniline at high temperature in the
presence of copper powder. N-Methylcarbamate, 3o, was obtained
by alkylation of URB602 in basic conditions. Acid hydrolysis of acetal
3i afforded 3n. Urea, 4a, was synthesized by the addition of 1c and cy-
clohexylamine to CDI. Amide 5 was prepared from the corresponding
acid via acyl chloride; thiocarbamate 6was prepared by the addition of
1c and cyclohexanethiol to CDI.
N-Aryl-O-alkylcarbamates, 3a–3l
CDI (0.648 g, 4 mmol; 3e: 0.324 g, 2 mmol) and triethylamine (TEA)
(0.71 ml, 5 mmol) were added to a stirred solution of the suitable amine
(1) (2 mmol) in dry CH3CN (22 ml). After the reactants were refluxed for
4 hr (2 hr: 3h, 3i, 3k, 3l; 8 hr: 3g; 20 hr: 3b, 3j), the appropriate alcohol,
2 (2 mmol), was added, and the mixture reacted for the appropriate
amount of time (3f: 1 hr; 3c–3e, 3j: 2 hr; 3h, 3i, 3k: 4 hr; 3g: 8 hr; 3l:
9 hr; 3a, 3b: 20 hr). In some cases, an additional amount of alcohol
(3d, 3e: 1 mmol; 3a: 6 mmol) and heating (3d, 3e: 0.5 hr; 3a: 24 hr)
were necessary. The mixture was cooled and concentrated. Purifica-
tion of the residue by column chromatography (cyclohexane:EtOAc,
9:1: 3a, 3d, 3f, 3j; 85:15: 3c; 8:2: 3b, 3e, 3g, 3l; 7:3; then EtOAc:MeOH,
98:2: 3h; petroleum ether:EtOAc, 75:25: 3i) and, in the case of solids,
recrystallization gave the desired compounds.
(5-Phenylpentyl)carbamic Acid Cyclohexyl Ester, 3a
3a appeared as a colorless oil. Yield: 26% (0.150 g). MS (EI): 289 (M+);
207 (100). 1H-NMR (CDCl3): 1.28–1.93 (m, 16H); 2.62 (t, 2H); 3.16 (t, 2H);
4.64 (br s, 2H); 7.16–7.32 (m, 5H) ppm. IR (Neat): 3344, 3083, 3064,
3021, 2932, 2847, 1689.
Phenylcarbamic Acid Cyclohexyl Ester, 3b
3b appeared as white crystals. Yield: 91% (0.399 g). Mp: 81C–83C
(petroleum ether; sealed capillary tube) (lit. 81C–82C). MS (EI): 219
(M+); 93 (100). 1H-NMR and IR are according to the literature [34].
Biphenyl-3-ylcarbamic Acid 5-Phenylpentyl Ester, 3c
3c appeared as white tufts. Yield: 96% (0.689 g). Mp: 92C–93C
(EtOH; sealed capillary tube). MS (EI): 359 (M+); 91 (100). 1H-NMR
(CDCl3): 1.45–1.80 (m, 6H); 2.65 (t, 2H); 4.19 (t, 2H); 6.66 (br s, 1H);
7.17–7.66 (m, 14H) ppm. IR (Nujol): 3316, 1703.
(30-Methylbiphenyl-3-yl)carbamic Acid Cyclohexyl Ester, 3d
3d appeared as a yellow oil. Yield: 35% (0.216 g). MS (EI): 309 (M+);
183 (100). 1H-NMR (CDCl3): 1.26–1.94 (m, 10H); 2.42 (s, 3H); 4.78
(m, 1H); 6.60 (d, 1H); 7.15–7.67 (m, 8H) ppm. IR (Neat): 3321, 3055,
3022, 2925, 2849, 1730, 1698.
(30-Trifluoromethylbiphenyl-3-yl)carbamic Acid Cyclohexyl
Ester, 3e
3e appeared as white needles. Yield: 56% (0.406 g). Mp: 72C–74C
(petroleum ether). MS (EI): 363 (M+); 281 (100). 1H-NMR (CDCl3):
1.26–1.99 (m, 10H); 4.78 (m, 1H); 6.67 (br s, 1H); 7.30–7.83 (m, 8H)
ppm. IR (Nujol): 3321, 1692.
Table 2. Continued
Compound Structure IC50 (mM)
4a 115 (n = 2)
5 >300
6 >300
Data are expressed as mean ± SEM (n = 3).65, December 2007 ª2007 Elsevier Ltd All rights reserved 1361
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Ester, 3f
3f appeared as a pale-yellow oil. Yield: 13% (0.101 g). MS (EI): 387 (M+);
287 (100). 1H-NMR (CDCl3): 1.27–1.90 (m, 10H); 4.74 (m, 1H); 6.56 (br s,
1H); 6.73–7.59 (m, 13H) ppm. IR (Neat): 3397, 3316, 1714.
Biphenyl-2-ylcarbamic Acid Cyclohexyl Ester, 3g
3g appeared as a brown oil. Yield: 97% (0.572 g). MS (EI): 295 (M+);
169 (100). 1H-NMR (CDCl3): 1.27–1.91 (m, 10H); 4.73 (m, 1H); 6.59
(s, 1H); 7.08–7.55 (m, 8H); 8.14 (d, 1H) ppm. IR (Nujol): 3421, 1728.
Biphenyl-3-ylcarbamic Acid 2,3-Dihydroxypropyl Ester, 3h
3h appeared as a white solid. Yield: 21% (0.121 g). Mp: 130C–132C
(EtOAc/petroleum ether; sealed capillary tube). MS (EI): 287 (M+); 195
(100). 1H-NMR (d6-acetone): 3.58 (d, 2H); 3.88 (m, 2H); 4.20 (m, 3H);
7.29–7.66 (m, 8H); 7.91 (s, 1H); 8.80 (s, 1H) ppm. IR (Neat): 3362,
1790, 1714.
Biphenyl-3-ylcarbamic Acid 2,2-Dimethyl[1,3]dioxan-5-yl
Ester, 3i
3i appeared as white crystals. Yield: 64% (0.419 g). MS (EI): 327 (M+);
195 (100). Mp: 116C–117C [(i-Pr)2O].
1H-NMR (CDCl3): 1.49 (d, 6H);
3.92–4.24 (m, 4H); 4.74 (m, 1H); 6.95 (s, 1H); 7.29–7.65 (m, 9H) ppm. IR
(Nujol): 3348, 1725.
Biphenyl-3-ylcarbamic Acid Biphenyl-3-yl Ester, 3j
3j appeared as pearly crystals. Yield: 18% (0.131 g). Mp: 166C–169C
(EtOH; sealed capillary tube). MS (EI): 365 (M+); 115 (100). 1H-NMR
(CDCl3): 7.07 (br s, 1H); 7.18–7.24 (m, 1H); 7.33–7.51 (m, 12H); 7.59–
7.64 (m, 4H); 7.78 (br s, 1H) ppm. IR (Nujol): 3337, 1704.
Biphenyl-4-ylcarbamic Acid Cyclohexyl Ester, 3k
3k appeared as white crystals. Yield: 37% (0.218 g). Mp: 142C–143C
(EtOH). MS (EI): 295 (M+), 213 (100). 1H-NMR (CDCl3): 1.26–1.95
(m, 10H); 4.78 (m, 1H); 6.65 (s, 1H); 7.32–7.60 (m, 9H) ppm. IR (Nujol):
3376, 3338, 1698.
Biphenyl-3-ylcarbamic Acid Phenyl Ester, 3l
3l appeared as pearly crystals. Yield: 15% (0.088 g). Mp: 84C–85C
(EtOH). MS (EI): 289 (M+); 94 (100). 1H-NMR (CDCl3): 7.08 (br s, 1H);
7.25 (m, 3H); 7.42 (m, 8H); 7.62 (m, 2H); 7.77 (br s, 1H) ppm. IR (Nujol):
3293, 1710.
(30-Methylbiphenyl-3-yl)carbamic Acid 2-Hydroxy-1-
hydroxymethylethyl Ester, 3m
CDI (1.754 g, 10.83 mmol) and TEA (2.5 ml, 34.5 mmol) were added to
a solution of 30-methylbiphenyl-3-ylamine (1d) (1.03 g, 5.63 mmol) in
dry CH3CN (80 ml). The mixture was refluxed for 2 hr, 2a was then
added (0.740 g, 5.61 mmol), and the mixture was again refluxed (4 hr).
The solvent was evaporated, and purification of the residue by column
chromatography (8:2 cyclohexane:EtOAc) gave a sample (0.800 g) of
(30-methylbiphenyl-3-yl)carbamic acid 2,2-dimethyl[1,3]dioxan-5-yl
ester (MS [EI]: 341 [M+], 209 [100]) and a product whose Rf corre-
sponds to that of 1d (approximate ratio of 1:1 by TLC). This mixture
was added to a 1:50 mixture of 37% HCl:THF (20 ml) and was allowed
to react under stirring at room temperature overnight. The solvent was
evaporated, and purification of the residue by column chromatography
(EtOAc) gave 3m as a colorless, fruity-smelling oil that solidified in the
freezer and, after recrystallization, turned into a white solid. Yield: 27%
(0.450 g). Mp: 100C–103C (EtOAc/petroleum ether; sealed capillary
tube). MS (EI): 301 (M+); 209 (100). 1H-NMR (d6-acetone): 2.40 (s, 3H);
3.76 (m, 4H); 3.95 (m, 2H); 4.87 (m, 1H); 7.57 (m, 1H); 7.16–7.46 (m, 6H);
7.93 (t, 1H); 8.70 (s, 1H) ppm. IR (Neat): 3342, 2926, 1710.1. (30-meth-
Figure 4. Structure of the MGL Inhibitor SPB 014031362 Chemistry & Biology 14, 1357–1365, December 2007 ª20ylbiphenyl-3-yl)-3-(30-methylbiphenyl-4-yl)urea (4b) (0.230 g; Mp:
214C–217C [EtOH]; MS [EI]: 392 [M+], 209 [100]; 1H-NMR [CDCl3]:
2.09 [s, 6H]; 7.17–7.99 [m, 14H]; 7.89 [m, 2H]; 8.28 [s, 2H]. IR [Nujol]:
3287, 1710) was also isolated as a side product of the reaction.
Biphenyl-3-ylcarbamic Acid 2-Hydroxy-1-
hydroxymethylethyl Ester, 3n
3i (0.170 g; 0.52 mmol) was added to a 1:50 mixture of 37% HCl:THF
(8 ml), and the solution reacted under stirring at room temperature for
3 hr. The mixture was quenched with 2N NaHCO3 and extracted with
EtOAc. The organic phase was dried and concentrated. Purification of
the residue by column chromatography (200:5 EtOAc:MeOH) and re-
crystallization gave 3n as colorless crystals. Yield: 40% (0.060 g).
Mp: 100C–102C (EtOAc/petroleum ether; sealed capillary tube).
MS (EI): 287 (M+); 195 (100). 1H-NMR (d6-acetone): 3.75 (m, 4H);
3.97 (br s, 2H); 4.86 (m, 1H); 7.29–7.67 (m, 8H); 7.94 (s, 1H); 8.72
(s, 1H) ppm. IR (Neat): 3289, 1779, 1692.
Biphenyl-3-ylmethylcarbamic Acid Cyclohexyl Ester, 3o
Cs2CO3 (0.420 g, 1.29 mmol) and tetrabutylammonium iodide (0.480 g,
1.29 mmol) were added to a solution of URB602 (0.127 g, 0.43 mmol) in
dry DMF (5 ml). The mixture was stirred at room temperature for
30 min, CH3I (0.183 g, 0.8 ml, 1.29 mmol) was added, and the mixture
was allowed to react further (8 hr). H2O was then added, and the mix-
ture was extracted with EtOAc. The organic phase was washed with
brine, dried, and concentrated. Purification of the residue by column
chromatography (7:3 cyclohexane:EtOAc) afforded 3o as a colorless
oil. Yield: 49% (0.065 g). MS (EI): 309 (M+); 152 (100). 1H-NMR
(CDCl3): 1.26–1.84 (m, 10H); 3.36 (s, 3H); 4.77 (m, 1H); 7.32–7.60
(m, 9H) ppm. IR (Neat): 3061, 3033, 2930, 2849, 1698.
1-(Biphenyl-3-yl)-3-cyclohexyl Urea, 4a
TEA (0.253 g, 0.35 ml, 2.5 mmol) was added to a solution of 1c (0.169 g,
2 mmol) and CDI (0.324 g, 2 mmol) in dry CH3CN (11 ml), and the mix-
ture was stirred under reflux for 2 hr. Then, cyclohexylamine (0.099 g,
2.5 mmol, 0.105 ml) was added, and the mixture was stirred under
reflux for 4 hr and was concentrated. Purification of the residue by col-
umn chromatography (8:2 cyclohexane:EtOAc) and recrystallization
gave 4a as a white solid. Yield: 51% (0.300 g). Mp: 179C–183C
(EtOH). MS (EI): 294 (M+); 169 (100). 1H-NMR (d6-acetone): 0.90–1.72
(m, 10H); 3.38 (m, 1H); 6.29 (m, 1H); 7.03–7.36 (m, 8H); 7.55 (s, 1H);
7.86 (br s, 1H) ppm. IR (Nujol): 3332, 1714.
N-Biphenyl-3-yl-2-cyclohexylacetamide, 5
Oxalyl chloride (0.508 g, 0.35 ml, 4 mmol) was added under nitrogen to
a cooled (0C) solution of cyclohexylacetic acid (0.142 g, 0.14 ml,
1 mmol) in dry THF (3.3 ml). The mixture was stirred at room tempera-
ture for 2 hr and concentrated, and the residue was dissolved in CH2Cl2
(3.3 ml). TEA (0.283 g, 0.39 ml, 2.8 mmol) and 1c (0.220 g, 1.3 mmol) in a
minimal amount of CH2Cl2 were added, the mixture was stirred for 20 hr,
and the solvent was concentrated. The purification of the residue by
column chromatography (75:25 cyclohexane:EtOAc) and recrystalliza-
tion gave5asa white, fluffy solid. Yield: 48% (0.140g). Mp: 108C–109C
(EtOH). MS (EI): 293 (M+); 169 (100) 1H-NMR (CDCl3): 0.93–1.97 (m, 11H);
2.25 (d, 2H); 7.30–7.62 (m, 9H); 7.79 (s, 1H) ppm. IR (Nujol): 3283, 1649.
Biphenyl-3-ylthiocarbamic Acid S-Cyclohexyl Ester, 6
CDI (0.648 g, 4 mmol) and TEA (0.515 g, 0.71 ml, 5.1 mmol) were added
to a solution of 1d (0.372 g, 2.2 mmol) in dry CH3CN (2 ml). After reflux-
ing for 4 hr, cyclohexanethiol (0.232 g, 0.25 ml, 2 mmol) was added.
The mixture was refluxed for 3 hr, cooled, and evaporated. Purification
of the residue by column chromatography (9:1 cyclohexane:EtOAc)
and recrystallization gave 6 as pale-yellow crystals. Yield: 70%
(0.435 g). Mp: 108C–111C (EtOH, sealed capillary tube). MS (EI):
311 (M+); 195 (100). 1H-NMR (d6-DMSO): 1.22–2.09 (m, 10H); 3.57
(m, 1H); 7.09 (br s, 1H); 7.25–7.71 (m, 9H) ppm. IR (Nujol): 3294,
3137, 3082, 1643.
3-(30-Substituted)phenylanilines, 1d and 1e
Pd(PPh3)4 (0.282 mg, 0.244 mmol), a solution of Na2CO3 (3.990 g, 37.6
mmol) in H2O (18 ml), and a solution of the suitable 3-substituted phe-
nylboronic acid (6.72 mmol) in EtOH (18 ml) were added to a stirred
solution of 3-bromoaniline (1.032 g, 6 mmol) in toluene (42 ml). The
mixture was vigorously stirred under reflux for 1 hr, cooled, added to07 Elsevier Ltd All rights reserved
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cannabinoid Levels in Rat Brain Slices
(A and B) Effects of URB602 (100 mM) or vehicle
(0.1% DMSO in DMEM) on (A) 2-AG levels, (B)
anandamide levels, and (C) PEA levels in rat
organotypic hippocampal slices in culture. Re-
sults are expressed as mean ± SEM (n = 4–5).
**p < 0.01, ns = not significant, unpaired Stu-
dent’s t test.water, and extracted with EtOAc. The combined organic layers were
dried and concentrated. Purification of the residue by column chroma-
tography (8:2 cyclohexane:EtOAc) and, in the case of 1e, recrystalliza-
tion gave 1d and 1e.
30-Methylbiphenyl-3-ylamine, 1d
1d appeared as an opaque, yellow oil that solidifies in the freezer.
Yield: 56% (0.614 g). Mp: 45.5C–46.5C (trituration with petroleum
ether). MS (EI): 183 (M+, 100). 1H-NMR (CDCl3): 2.43 (s, 3H); 3.72
(br s, 2H); 6.70 (m, 1H); 6.93 (t, 1H); 7.01 (m, 1H); 7.15–7.40 (m, 5H)
ppm. IR (Neat): 3457, 3376, 3213, 3028, 2919, 2843, 1622, 1600.
30-Trifluoromethylbiphenyl-3-ylamine, 1e
1e appeared as colorless needles. Yield: 43% (0.610 g). Mp: 40C–
42C (petroleum ether). MS (EI): 237 (M+, 100). 1H-NMR (CDCl3):
3.83 (br s, 2H); 6.74 (m, 1H); 6.97 (m, 2H); 7.27 (m, 1H); 7.56 (m, 2H);
7.78 (m, 2H) ppm. IR (Nujol): 3446, 3332, 3196, 1622.
3-(Biphenyl-3-yloxy)phenylamine, 1f
3-Bromoaniline (1.672 g, 1.16 ml, 10.65 mmol) and copper (0.630 g,
10 mmol) were added to a cooled (0C) solution of potassium 3-phe-
nylphenolate (obtained by adding 3-phenylphenol [1.81 g, 10.65
mmol] to a solution of potassium [0.410 g, 10.65 mmol] in dry MeOH
[40 ml], stirring the mixture for 0.5 hr at room temperature, evaporating
the solvent, and drying the residue). The mixture was stirred at 160C–
170C for 12 hr, cooled, and concentrated. Purification of the residue
by column chromatography (8:2 cyclohexane:EtOAc) gave 1f as
a brown oil. Yield: 23% (0.642 g). MS (EI): 261 (M+); 170 (100).
1H-NMR (CDCl3): 3.70 (br s, 2H); 6.44 (m, 2H); 6.99–7.61 (m, 11H)
ppm. IR (Neat): 3468, 3381, 3218, 3066, 3033, 2925, 2849, 1736.
MGL Cloning
Rat MGL cDNA was cloned out of the pBluescript-SK vector by using
the following primers: 50-CGCGGCAGCCATATGCTGAGGCAAGTTCA
CC-30 (forward primer) and 50-AGCAGCCGGATCCTCTCAGGGTAG
ACACCTAG-30 (reverse primer). These primers introduced a BamHI
and an NdeI endonuclease restriction site at the 50 and 30 end, respec-
tively, of the cDNA. Platinum Pfx DNA polymerase (Invitrogen, Carls-
bad, CA) was used to run the polymerase chain reaction (PCR),
followed by a BamHI/NdeI double digest of the PCR product and the
pET15b vector (Novagen, La Jolla, CA) containing an N-terminal histi-
dine tag. The vector and the PCR product were ligated by using T4
DNA ligase (Promega, Madison, WI) after the dephosphorylation of
the pET15b vector DNA. The ligation setup was transformed into
DH5a E. coli cells and were plated on a Luria Broth agar plate contain-
ing 50 mg/ml ampicillin. Ten colonies were selected, and their plasmid
DNAs were purified according to the QIAGEN plasmid DNA miniprep
Kit protocol (QIAGEN, Valencia, CA). Restriction digest analysis
resulted in four positive clones, which were subjected to DNA
sequencing, confirming the correct sequence.
MGL Expression and Purification
Clone 2 was expressed in Rosetta 2(DE3)pLysS E. coli cells (Novagen)
at 37C by using 1 mM isopropyl-b-D-thiogalactopyranoside (IPTG).
This clone was used for all subsequent protein expression experi-
ments. 4 L LB plus 50 mg/ml ampicillin was inoculated with 40 ml over-Chemistry & Biology 14, 1357–136night culture of Rosetta 2(DE3)pLysS cells transformed with pET15b/
MGL grown in LB plus 50 mg/ml ampicillin. Cells were grown at 37C
until the optical density (OD) at 600 nm reached 0.8. At this point,
addition of IPTG to a final concentration of 1 mM induced MGL over-
expression. After 4 hr, the cells were harvested by centrifugation at
6,000 3 g for 15 min, and the bacterial pellet was resuspended in
100 ml lysis buffer (50 mM HEPES [pH 7.4], 300 mM NaCl, 10 mM
MgCl2, 3 mM b-mercaptoethanol, 0.5 mM benzamidine, 10 mM E-64,
and 10 mg/ml aprotinin). The cells were lysed by using a French press,
and the cell lysate was centrifuged at 3,000 3 g for 1 hr at 4C to sep-
arate the membrane fraction from the cell debris. The supernatant
(membrane fraction) was then subjected to another centrifugation at
35,000 3 g for 1 hr at 4C. The pellet was resuspended in 50 mM
HEPES (pH 7.4), 300 mM NaCl, 3 mM b-mercaptoethanol, 1% Triton
X-100; stirred for 30 min, and centrifuged again at 5,000 3 g for
1 hr at 4C. The supernatant was loaded onto a TALON column (Clon-
tech, Mountain View, CA) equilibrated with 50 mM HEPES (pH 7.4),
300 mM NaCl, 3 mM b-mercaptoethanol, 0.1% Triton X-100 (buffer A).
The column was washed with five volumes of buffer A, and the protein
was subsequently eluted from the column by using a step gradient of
imidazole ranging from 10 to 200 mM imidazole in buffer A (five column
volumes each). The protein eluted at 75 mM imidazole.
Protein Analysis
The protein concentration of the purified MGL was determined by Coo-
massie blue staining by using fatty acid-free bovine serum albumin
(BSA) (Sigma-Aldrich) as a standard. SDS-PAGE and western blot
were performed as previously described [35], by using 4%–20%
Tris-glycine gels (Invitrogen). For western blot, proteins were trans-
ferred onto an Immun-Blot PVDF membrane (BioRad, Hercules, CA)
by using a Semiphor Transphor Unit (Amersham, Piscataway, NJ)
and were incubated with a rabbit MGL antibody [12]. Immunoreactive
bands were visualized by using the ECL-Plus Kit (Amersham).
Cerebellar Membrane Preparation
Male Wistar rats were anesthetized by halothane and decapitated, and
cerebella (minus the brainstem) were dissected and placed immedi-
ately in 10 volumes of ice-cold 20 mM Tris (pH 7.5) with 0.32 M
sucrose. Tissue was homogenized and potterized, then centrifuged
at 1,000 3 g for 10 min at 4C. The supernatant was removed and
subjected to further centrifugation at 27,000 3 g for 30 min at 4C.
The pellet was resuspended in 50 mM Tris (pH 7.5). The protein con-
centration was measured by Bradford Assay.
Measurement of MGL Activity
The final reaction consisted of 0.445 ml assay buffer (50 mM Tris-HCL
[pH 8.0], 0.5 mg/ml BSA, fatty acid-free) containing either 10 ng puri-
fied E. coliMGL, 200 ng nonpurified HeLa MGL [12], or 50 mg cerebellar
membranes, 50 ml 2-OG (prepared in assay buffer, 10 mM final), and 5 ml
URB602, MAFP, or NAM (prepared in DMSO), for a final total reaction
volume of 0.5 ml. The final concentration of vehicle (1% DMSO) had no
effect on MGL activity. After a 10 min incubation at 37C, reactions
were stopped by the addition of 3 ml chloroform:methanol (2:1, vol:vol),5, December 2007 ª2007 Elsevier Ltd All rights reserved 1363
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as an internal standard. After centrifugation at 2,000 3 g at 4C for
10 min, the organic layers were collected and dried under N2. The
residues were suspended in 50 ml chloroform:methanol (1:3, vol:vol)
and analyzed by LC/MS. We used a reverse-phase XDB Eclipse C18
column (50 3 4.6 mm i.d., 1.8 mm, Agilent Technologies, Wilmington,
DE) eluted with a linear gradient from 90% to 100% of A in B for
2.5 min at a flow rate of 1.5 ml/min with the column temperature at
40C. Mobile phase A consisted of methanol containing 0.25% acetic
acid and 5 mM ammonium acetate; mobile phase B consisted of water
containing 0.25% acetic acid and 5 mM ammonium acetate. ESI was
in the negative mode, capillary voltage was set at 4 kV, and the frag-
mentor voltage was 100 V. N2 was used as a drying gas at a flow
rate of 13 l/min and a temperature of 350C. Nebulizer pressure was
set at 60 psi. For quantification purposes, we monitored the [M-H]
ions ofm/z = 281.3 for oleic acid andm/z = 269 for heptadecanoic acid.
Measurement of URB602
Samples containing either URB602 (300 mM), MGL (1.4 pM), or both
URB602 and MGL were incubated at 37C for 30 min in assay buffer.
At various time points, the reaction was stopped with an equal volume
of ice-cold methanol and was directly analyzed in positive ionization
mode by LC/MS. We used a SB-CN column (150 3 2.1 mm i.d.,
5 mm, Agilent) eluted with a linear gradient of methanol in water con-
taining 0.25% acetic acid and 5 mM ammonium acetate (from 60%
to 100% of methanol in 8 min) at a flow rate of 0.5 ml/min with the
column temperature at 50C. Capillary voltage was set at 4 kV, and
fragmentor voltage was 100 V. Nebulizer pressure was set at 60 psi.
N2 was used as a drying gas at a flow rate of 13 l/min and a temperature
of 350C. ESI was in the positive mode, and a full scan spectrum was
acquired from m/z = 100 to 600. Extracted ion chromatograms were
used to quantify URB602 ([M+H]+, m/z = 296).
Hippocampal Slice Cultures
Hippocampal organotypic slice cultures were prepared from Wistar
rats as previously described [36]. Briefly, postnatal day-9 rats were
sacrificed by cryoanesthesia, hippocampi were dissected from 0.4 mm
coronal slices prepared by using a vibratome, and three hippocampi
per well were incubated in Neurobasal medium on Millicell culture
inserts (Millipore, Billerica, MA). Slices were maintained for 8 days at
37C with 5% CO2 before treatment with either URB602 (100 mM) or
vehicle (0.1% DMSO in DMEM) for 25 min at 37C. Reactions were
stopped by a wash with ice-cold PBS, followed by fixation with 4%
paraformaldehyde for 30 min at room temperature. Slices were then
extracted in 1 ml ice-cold methanol:chloroform:water (1:1:2, vol:vol:vol)
containing 500 pmol 2-[2H8]-AG and 10 pmol each of [
2H4]-ananda-
mide and [2H4]-palmitylethanolamide, added as internal standards.
Organic phases were recovered, evaporated under N2, reconstituted
in 50 ml chloroform:methanol (1:3, vol:vol), and analyzed by LC/MS
as previously described [18].
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